{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:13:01Z","timestamp":1788541981036,"version":"build-2803163510"},"reference-count":78,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to identify potential drugs associated with diabetes insipidus (DI) and track its epidemiological characteristics using the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective pharmacovigilance analysis was conducted on FAERS data from Q1 2004 to Q4 2024. Disproportionality analyses were performed using the reporting odds ratio and the Bayesian confidence propagation neural network (BCPNN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 2,189 cases of DI were recorded in FAERS, with a median age of 47.0 years (interquartile range (IQR) 27.0\u201360.0). Disproportionality analysis identified 71 drugs with positive signals, in which nervous system agents (22 drugs, 31.0%), antineoplastic agents (15 drugs, 21.1%), and systemic anti-infectives (14 drugs, 19.7%) constituted the top three drug classes. Lithium (\n                      <jats:italic>n<\/jats:italic>\n                      = 114, information component at the 95% lower credibility interval (IC\n                      <jats:sub>025<\/jats:sub>\n                      ) = 6.12) and dexmedetomidine (\n                      <jats:italic>n<\/jats:italic>\n                      = 105, IC\n                      <jats:sub>025<\/jats:sub>\n                      = 6.79) were identified as the most frequently reported drugs and showed the strongest association with DI. Several drugs, such as aripiprazole, letrozole, tigecycline, and dapagliflozin, were found to have unexpected potential associations with DI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides a comprehensive overview of drug-induced DI based on real-world data. It highlights the importance of monitoring patients for DI when using certain medications, particularly high-risk nervous system drugs and antineoplastic agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-25-0734","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:47:52Z","timestamp":1765543672000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":1,"title":["Real-world pharmacovigilance study of drug-induced diabetes insipidus from the FAERS database"],"prefix":"10.1530","volume":"15","author":[{"given":"Hui","family":"Lv","sequence":"first","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Lan","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3657-1123","authenticated-orcid":true,"given":"Nonger","family":"Shen","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Horm Res Paediatr","first-page":"69","article-title":"Diabetes insipidus \u2013 diagnosis and management","volume":"77","author":"Di Iorgi N","year":"2012","unstructured":"Di Iorgi N\n, \nNapoli F\n, \nAllegri AE\n, et al.\n Diabetes insipidus \u2013 diagnosis and management. Horm Res Paediatr 2012 77 69\u201384. (https:\/\/doi.org\/10.1159\/000336333)"},{"key":"bib2","series-title":"Cureus","article-title":"Diabetes insipidus: pathogenesis, diagnosis, and clinical management","volume":"13","author":"Mutter CM","year":"2021","unstructured":"Mutter CM\n, \nSmith T\n, \nMenze O\n, et al.\n Diabetes insipidus: pathogenesis, diagnosis, and clinical management. Cureus 2021 13 e13523. (https:\/\/doi.org\/10.7759\/cureus.13523)"},{"key":"bib3","series-title":"Endocr Connect","first-page":"1281","article-title":"Changing the name of diabetes insipidus: a position statement of the working group for renaming diabetes insipidus","volume":"11","author":"Working Group for Renaming Diabetes Insipidus","year":"2022","unstructured":"Working Group for Renaming Diabetes Insipidus, \nArima H\n, \nCheetham T\n, et al.\n Changing the name of diabetes insipidus: a position statement of the working group for renaming diabetes insipidus. Endocr Connect 2022 11 1281\u20131284. (https:\/\/doi.org\/10.1530\/ec-22-0378)"},{"key":"bib4","series-title":"J Intern Med","first-page":"73","article-title":"Diagnosis and management of diabetes insipidus for the internist: an update","volume":"290","author":"Christ-Crain M","year":"2021","unstructured":"Christ-Crain M\n, \nWinzeler B\n & \nRefardt J\n\n. Diagnosis and management of diabetes insipidus for the internist: an update. J Intern Med 2021 290 73\u201387. (https:\/\/doi.org\/10.1111\/joim.13261)"},{"key":"bib5","series-title":"J Neuroendocrinol","article-title":"New developments and concepts in the diagnosis and management of diabetes insipidus (AVP-deficiency and resistance)","volume":"35","author":"Angelousi A","year":"2023","unstructured":"Angelousi A\n, \nAlexandraki KI\n, \nMytareli C\n, et al.\n New developments and concepts in the diagnosis and management of diabetes insipidus (AVP-deficiency and resistance). J Neuroendocrinol 2023 35 e13233. (https:\/\/doi.org\/10.1111\/jne.13233)"},{"key":"bib6","series-title":"Nephrol Dial Transplant","first-page":"2120","article-title":"Treatment and long-term outcome in primary nephrogenic diabetes insipidus","volume":"38","author":"Lopez-Garcia SC","year":"2020","unstructured":"Lopez-Garcia SC\n, \nDownie ML\n, \nKim JS\n, et al.\n Treatment and long-term outcome in primary nephrogenic diabetes insipidus. Nephrol Dial Transplant 2020 38 2120\u20132130. (https:\/\/doi.org\/10.1093\/ndt\/gfaa243)"},{"key":"bib7","series-title":"J Pediatr Endocrinol Metab","first-page":"1089","article-title":"Evaluation of the etiological and clinical characteristics of pediatric central diabetes insipidus","volume":"35","author":"Gasimova E","year":"2022","unstructured":"Gasimova E\n, \nBerberoglu M\n, \nOzsu E\n, et al.\n Evaluation of the etiological and clinical characteristics of pediatric central diabetes insipidus. J Pediatr Endocrinol Metab 2022 35 1089\u20131096. (https:\/\/doi.org\/10.1515\/jpem-2022-0058)"},{"key":"bib8","series-title":"Drug Saf","first-page":"449","article-title":"Drug-induced diabetes insipidus: incidence, prevention and management","volume":"21","author":"Bendz H","year":"1999","unstructured":"Bendz H\n & \nAurell M\n\n. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf 1999 21 449\u2013456. (https:\/\/doi.org\/10.2165\/00002018-199921060-00002)"},{"key":"bib9","series-title":"Front Oncol","article-title":"Immune checkpoint inhibitor-induced central diabetes insipidus: looking for the needle in the haystack or a very rare side-effect to promptly diagnose?","volume":"12","author":"Barnabei A","year":"2022","unstructured":"Barnabei A\n, \nStrigari L\n, \nCorsello A\n, et al.\n Immune checkpoint inhibitor-induced central diabetes insipidus: looking for the needle in the haystack or a very rare side-effect to promptly diagnose? Front Oncol 2022 12 798517. (https:\/\/doi.org\/10.3389\/fonc.2022.798517)"},{"key":"bib10","series-title":"Cureus","article-title":"Diabetes insipidus: a pragmatic approach to management","volume":"13","author":"Priya G","year":"2021","unstructured":"Priya G\n, \nKalra S\n, \nDasgupta A\n, et al.\n Diabetes insipidus: a pragmatic approach to management. Cureus 2021 13 e12498. (https:\/\/doi.org\/10.7759\/cureus.12498)"},{"key":"bib11","series-title":"Int J Med Sci","first-page":"796","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda T","year":"2013","unstructured":"Sakaeda T\n, \nTamon A\n, \nKadoyama K\n, et al.\n Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 2013 10 796\u2013803. (https:\/\/doi.org\/10.7150\/ijms.6048)"},{"key":"bib12","series-title":"Clin Exp Ophthalmol","first-page":"140","article-title":"Drug-associated glaucoma: a real-world study based on the Food and Drug Administration adverse event reporting system database","volume":"53","author":"Wu SN","year":"2024","unstructured":"Wu SN\n, \nChen XD\n, \nYan D\n, et al.\n Drug-associated glaucoma: a real-world study based on the Food and Drug Administration adverse event reporting system database. Clin Exp Ophthalmol 2024 53 140\u2013160. (https:\/\/doi.org\/10.1111\/ceo.14454)"},{"key":"bib13","series-title":"Front Pharmacol","article-title":"Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: a pharmacovigilance study of the FAERS database","volume":"14","author":"Zhao H","year":"2023","unstructured":"Zhao H\n, \nLi ZR\n, \nZhang Q\n, et al.\n Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: a pharmacovigilance study of the FAERS database. Front Pharmacol 2023 14 1110575. (https:\/\/doi.org\/10.3389\/fphar.2023.1110575)"},{"key":"bib14","series-title":"Acta Endocrinol","first-page":"270","article-title":"Lithium-induced nephrogenic diabetes insipidus responsive to desmopressin","volume":"15","author":"Senocak TE","year":"2019","unstructured":"Senocak TE\n, \nEralp H\n & \nKayatas K\n\n. Lithium-induced nephrogenic diabetes insipidus responsive to desmopressin. Acta Endocrinol 2019 15 270\u2013271. (https:\/\/doi.org\/10.4183\/aeb.2019.270)"},{"key":"bib15","series-title":"Cells","first-page":"1060","article-title":"Lithium chloride and GSK3 inhibition reduce aquaporin-2 expression in primary cultured inner medullary collecting duct cells due to independent mechanisms","volume":"9","author":"Kaiser M","year":"2020","unstructured":"Kaiser M\n & \nEdemir B\n\n. Lithium chloride and GSK3 inhibition reduce aquaporin-2 expression in primary cultured inner medullary collecting duct cells due to independent mechanisms. Cells 2020 9 1060. (https:\/\/doi.org\/10.3390\/cells9041060)"},{"key":"bib16","series-title":"Nat Rev Dis Primers","first-page":"54","article-title":"Diabetes insipidus","volume":"5","author":"Christ-Crain M","year":"2019","unstructured":"Christ-Crain M\n, \nBichet DG\n, \nFenske WK\n, et al.\n Diabetes insipidus. Nat Rev Dis Primers 2019 5 54. (https:\/\/doi.org\/10.1038\/s41572-019-0103-2)"},{"key":"bib17","series-title":"Prim Care Companion CNS Disord","article-title":"Diabetes insipidus secondary to combination atypical antipsychotic and lithium use in a bipolar disorder patient: a case report","volume":"13","author":"Rej S","year":"2011","unstructured":"Rej S\n, \nMargolese HC\n & \nLow NC\n\n. Diabetes insipidus secondary to combination atypical antipsychotic and lithium use in a bipolar disorder patient: a case report. Prim Care Companion CNS Disord 2011 13 PCC.11l01138. (https:\/\/doi.org\/10.4088\/pcc.11l01138)"},{"key":"bib18","series-title":"Indian J Psychol Med","first-page":"94","article-title":"Diabetes insipidus induced by oral olanzapine at therapeutic dose","volume":"45","author":"Kumar MP","year":"2023","unstructured":"Kumar MP\n, \nRamamurthy P\n, \nSolomon S\n, et al.\n Diabetes insipidus induced by oral olanzapine at therapeutic dose. Indian J Psychol Med 2023 45 94\u201395. (https:\/\/doi.org\/10.1177\/02537176221109962)"},{"key":"bib19","series-title":"Anaesth Intensive Care","first-page":"319","article-title":"Diabetes insipidus following overdose of baclofen and quetiapine","volume":"37","author":"Silversides JA","year":"2009","unstructured":"Silversides JA\n & \nScott KC\n\n. Diabetes insipidus following overdose of baclofen and quetiapine. Anaesth Intensive Care 2009 37 319\u2013320. (https:\/\/doi.org\/10.1177\/0310057x0903700218)"},{"key":"bib20","series-title":"Paediatr Anaesth","first-page":"250","article-title":"Dexmedetomidine-associated diabetes insipidus during skull base surgery in a pediatric patient","volume":"33","author":"Reynolds EG","year":"2023","unstructured":"Reynolds EG\n, \nVan Decar LM\n, \nSharpe EE\n, et al.\n Dexmedetomidine-associated diabetes insipidus during skull base surgery in a pediatric patient. Paediatr Anaesth 2023 33 250\u2013253. (https:\/\/doi.org\/10.1111\/pan.14587)"},{"key":"bib21","series-title":"Anaesthesiol Intensive Ther","first-page":"237","article-title":"Dexmedetomidine-induced diabetes insipidus during coronary artery bypass graft surgery","volume":"55","author":"Tang T","year":"2023","unstructured":"Tang T\n, \nWagle R\n, \nHasoon J\n, et al.\n Dexmedetomidine-induced diabetes insipidus during coronary artery bypass graft surgery. Anaesthesiol Intensive Ther 2023 55 237\u2013239. (https:\/\/doi.org\/10.5114\/ait.2023.130859)"},{"key":"bib22","series-title":"J Pharm Pract","first-page":"685","article-title":"Probable dexmedetomidine induced diabetes insipidus: a case review","volume":"36","author":"Vani S","year":"2023","unstructured":"Vani S\n, \nStackpole A\n & \nKovacevic MP\n\n. Probable dexmedetomidine induced diabetes insipidus: a case review. J Pharm Pract 2023 36 685\u2013688. (https:\/\/doi.org\/10.1177\/08971900211053261)"},{"key":"bib23","series-title":"Anesth Analg","first-page":"82","article-title":"Perioperative diabetes insipidus caused by anesthetic medications: a review of the literature","volume":"134","author":"Van Decar LM","year":"2022","unstructured":"Van Decar LM\n, \nReynolds EG\n, \nSharpe EE\n, et al.\n Perioperative diabetes insipidus caused by anesthetic medications: a review of the literature. Anesth Analg 2022 134 82\u201389. (https:\/\/doi.org\/10.1213\/ane.0000000000005344)"},{"key":"bib24","series-title":"Am J Kidney Dis","first-page":"628","article-title":"Pemetrexed-induced nephrogenic diabetes insipidus","volume":"68","author":"Fung E","year":"2016","unstructured":"Fung E\n, \nAnand S\n & \nBhalla V\n\n. Pemetrexed-induced nephrogenic diabetes insipidus. Am J Kidney Dis 2016 68 628\u2013632. (https:\/\/doi.org\/10.1053\/j.ajkd.2016.04.016)"},{"key":"bib25","series-title":"Medicine","article-title":"Severe hyponatremia and diabetes insipidus caused by low-dose cyclophosphamide in breast cancer patients: a case report and literature review","volume":"103","author":"Chen Y","year":"2024","unstructured":"Chen Y\n, \nLi L\n, \nOu R\n, et al.\n Severe hyponatremia and diabetes insipidus caused by low-dose cyclophosphamide in breast cancer patients: a case report and literature review. Medicine 2024 103 e37572. (https:\/\/doi.org\/10.1097\/md.0000000000037572)"},{"key":"bib26","series-title":"CEN Case Rep","first-page":"194","article-title":"A case of ifosfamide-induced acute kidney injury, Fanconi syndrome, and nephrogenic diabetes insipidus","volume":"13","author":"Hoang S","year":"2024","unstructured":"Hoang S\n, \nPujar T\n, \nBellorin-Font E\n, et al.\n A case of ifosfamide-induced acute kidney injury, Fanconi syndrome, and nephrogenic diabetes insipidus. CEN Case Rep 2024 13 194\u2013198. (https:\/\/doi.org\/10.1007\/s13730-023-00829-z)"},{"key":"bib27","series-title":"J Oncol Pharm Pract","first-page":"1040","article-title":"Central diabetes insipidus induced by temozolomide: a report of two cases","volume":"27","author":"Mahiat C","year":"2021","unstructured":"Mahiat C\n, \nCapes A\n, \nDuprez T\n, et al.\n Central diabetes insipidus induced by temozolomide: a report of two cases. J Oncol Pharm Pract 2021 27 1040\u20131045. (https:\/\/doi.org\/10.1177\/1078155220961551)"},{"key":"bib28","series-title":"Front Endocrinol","article-title":"Grading central diabetes insipidus induced by immune checkpoint inhibitors: a challenging task","volume":"13","author":"Barnabei A","year":"2022","unstructured":"Barnabei A\n, \nStrigari L\n, \nCorsello A\n, et al.\n Grading central diabetes insipidus induced by immune checkpoint inhibitors: a challenging task. Front Endocrinol 2022 13 840971. (https:\/\/doi.org\/10.3389\/fendo.2022.840971)"},{"key":"bib29","series-title":"Best Pract Res Clin Endocrinol Metab","article-title":"Endocrine immune-related adverse events: adrenal, parathyroid, diabetes insipidus, and lipoatrophy","volume":"36","author":"Atkinson M","year":"2022","unstructured":"Atkinson M\n & \nLansdown AJ\n\n. Endocrine immune-related adverse events: adrenal, parathyroid, diabetes insipidus, and lipoatrophy. Best Pract Res Clin Endocrinol Metab 2022 36 101635. (https:\/\/doi.org\/10.1016\/j.beem.2022.101635)"},{"key":"bib30","series-title":"Life Sci","article-title":"Letrozole: pharmacology, toxicity and potential therapeutic effects","volume":"310","author":"Mukherjee AG","year":"2022","unstructured":"Mukherjee AG\n, \nWanjari UR\n, \nNagarajan D\n, et al.\n Letrozole: pharmacology, toxicity and potential therapeutic effects. Life Sci 2022 310 121074. (https:\/\/doi.org\/10.1016\/j.lfs.2022.121074)"},{"key":"bib31","series-title":"Endocrinology","first-page":"2092","article-title":"Estradiol and testosterone regulate arginine-vasopressin expression in SH-SY5Y human female neuroblastoma cells through estrogen receptors-\u03b1 and -\u03b2","volume":"154","author":"Grassi D","year":"2013","unstructured":"Grassi D\n, \nBellini MJ\n, \nAcaz-Fonseca E\n, et al.\n Estradiol and testosterone regulate arginine-vasopressin expression in SH-SY5Y human female neuroblastoma cells through estrogen receptors-\u03b1 and -\u03b2. Endocrinology 2013 154 2092\u20132100. (https:\/\/doi.org\/10.1210\/en.2012-2137)"},{"key":"bib32","series-title":"J Obstet Gynaecol Res","first-page":"2009","article-title":"Estrogen-dependent oxytocin expression in the hypothalamus and estrogen-dependent vasopressin in the median eminence","volume":"50","author":"Nishimura K","year":"2024","unstructured":"Nishimura K\n, \nUeta Y\n & \nYoshino K\n\n. Estrogen-dependent oxytocin expression in the hypothalamus and estrogen-dependent vasopressin in the median eminence. J Obstet Gynaecol Res 2024 50 2009\u20132018. (https:\/\/doi.org\/10.1111\/jog.16100)"},{"key":"bib33","series-title":"J Card Fail","first-page":"615","article-title":"Doxycycline for chronic driveline infections can cause diabetes insipidus","volume":"29","author":"Kesari A","year":"2023","unstructured":"Kesari A\n, \nSchreck T\n, \nBenatti RD\n, et al.\n Doxycycline for chronic driveline infections can cause diabetes insipidus. J Card Fail 2023 29 615. (https:\/\/doi.org\/10.1016\/j.cardfail.2022.10.171)"},{"key":"bib34","series-title":"Cancer Treat Rev","article-title":"Targeting neuroendocrine tumors with octreotide and lanreotide: key points for clinical practice from NET specialists","volume":"117","author":"La Salvia A","year":"2023","unstructured":"La Salvia A\n, \nModica R\n, \nRossi RE\n, et al.\n Targeting neuroendocrine tumors with octreotide and lanreotide: key points for clinical practice from NET specialists. Cancer Treat Rev 2023 117 102560. (https:\/\/doi.org\/10.1016\/j.ctrv.2023.102560)"},{"key":"bib35","series-title":"J Drug Target","first-page":"569","article-title":"Octreotide and octreotide-derived delivery systems","volume":"31","author":"Fan M","year":"2023","unstructured":"Fan M\n, \nHuang Y\n, \nZhu X\n, et al.\n Octreotide and octreotide-derived delivery systems. J Drug Target 2023 31 569\u2013584. (https:\/\/doi.org\/10.1080\/1061186x.2023.2216895)"},{"key":"bib36","series-title":"J ASEAN Fed Endocr Soc","first-page":"220","article-title":"Diabetes insipidus induced by combination of short-acting octreotide and lanreotide for recurrent carcinoid crisis of neuroendocrine tumour: a case report","volume":"36","author":"Guan GK","year":"2021","unstructured":"Guan GK\n, \nRajoo S\n, \nDusa NM\n, et al.\n Diabetes insipidus induced by combination of short-acting octreotide and lanreotide for recurrent carcinoid crisis of neuroendocrine tumour: a case report. J ASEAN Fed Endocr Soc 2021 36 220\u2013222. (https:\/\/doi.org\/10.15605\/jafes.036.02.09)"},{"key":"bib37","series-title":"Am J Med Sci","first-page":"517","article-title":"Effect of dapagliflozin treatment on fluid and electrolyte balance in diabetic rats","volume":"352","author":"Chen L","year":"2016","unstructured":"Chen L\n, \nLaRocque LM\n, \nEfe O\n, et al.\n Effect of dapagliflozin treatment on fluid and electrolyte balance in diabetic rats. Am J Med Sci 2016 352 517\u2013523. (https:\/\/doi.org\/10.1016\/j.amjms.2016.08.015)"},{"key":"bib38","series-title":"Am J Physiol Endocrinol Metab","first-page":"E633","article-title":"Dehydration-induced AVP stimulates glucagon release and ketogenesis","volume":"328","author":"Hill TG","year":"2025","unstructured":"Hill TG\n, \nBriant LJB\n, \nKim A\n, et al.\n Dehydration-induced AVP stimulates glucagon release and ketogenesis. Am J Physiol Endocrinol Metab 2025 328 E633\u2013E644. (https:\/\/doi.org\/10.1152\/ajpendo.00505.2024)"},{"key":"bib39","series-title":"Diagnostics","first-page":"1194","article-title":"Sodium-glucose cotransporter 2 inhibitor combined with conventional diuretics ameliorate body fluid retention without excessive plasma volume reduction","volume":"14","author":"Asakura-Kinoshita M","year":"2024","unstructured":"Asakura-Kinoshita M\n, \nMasuda T\n, \nOka K\n, et al.\n Sodium-glucose cotransporter 2 inhibitor combined with conventional diuretics ameliorate body fluid retention without excessive plasma volume reduction. Diagnostics 2024 14 1194. (https:\/\/doi.org\/10.3390\/diagnostics14111194)"},{"key":"bib1","series-title":"Horm Res Paediatr","first-page":"69","article-title":"Diabetes insipidus \u2013 diagnosis and management","volume":"77","author":"Di Iorgi N","year":"2012","unstructured":"Di Iorgi N\n, \nNapoli F\n, \nAllegri AE\n, et al.\n Diabetes insipidus \u2013 diagnosis and management. Horm Res Paediatr 2012 77 69\u201384. (https:\/\/doi.org\/10.1159\/000336333)"},{"key":"bib2","series-title":"Cureus","article-title":"Diabetes insipidus: pathogenesis, diagnosis, and clinical management","volume":"13","author":"Mutter CM","year":"2021","unstructured":"Mutter CM\n, \nSmith T\n, \nMenze O\n, et al.\n Diabetes insipidus: pathogenesis, diagnosis, and clinical management. Cureus 2021 13 e13523. (https:\/\/doi.org\/10.7759\/cureus.13523)"},{"key":"bib3","series-title":"Endocr Connect","first-page":"1281","article-title":"Changing the name of diabetes insipidus: a position statement of the working group for renaming diabetes insipidus","volume":"11","author":"Working Group for Renaming Diabetes Insipidus","year":"2022","unstructured":"Working Group for Renaming Diabetes Insipidus, \nArima H\n, \nCheetham T\n, et al.\n Changing the name of diabetes insipidus: a position statement of the working group for renaming diabetes insipidus. Endocr Connect 2022 11 1281\u20131284. (https:\/\/doi.org\/10.1530\/ec-22-0378)"},{"key":"bib4","series-title":"J Intern Med","first-page":"73","article-title":"Diagnosis and management of diabetes insipidus for the internist: an update","volume":"290","author":"Christ-Crain M","year":"2021","unstructured":"Christ-Crain M\n, \nWinzeler B\n & \nRefardt J\n\n. Diagnosis and management of diabetes insipidus for the internist: an update. J Intern Med 2021 290 73\u201387. (https:\/\/doi.org\/10.1111\/joim.13261)"},{"key":"bib5","series-title":"J Neuroendocrinol","article-title":"New developments and concepts in the diagnosis and management of diabetes insipidus (AVP-deficiency and resistance)","volume":"35","author":"Angelousi A","year":"2023","unstructured":"Angelousi A\n, \nAlexandraki KI\n, \nMytareli C\n, et al.\n New developments and concepts in the diagnosis and management of diabetes insipidus (AVP-deficiency and resistance). J Neuroendocrinol 2023 35 e13233. (https:\/\/doi.org\/10.1111\/jne.13233)"},{"key":"bib6","series-title":"Nephrol Dial Transplant","first-page":"2120","article-title":"Treatment and long-term outcome in primary nephrogenic diabetes insipidus","volume":"38","author":"Lopez-Garcia SC","year":"2020","unstructured":"Lopez-Garcia SC\n, \nDownie ML\n, \nKim JS\n, et al.\n Treatment and long-term outcome in primary nephrogenic diabetes insipidus. Nephrol Dial Transplant 2020 38 2120\u20132130. (https:\/\/doi.org\/10.1093\/ndt\/gfaa243)"},{"key":"bib7","series-title":"J Pediatr Endocrinol Metab","first-page":"1089","article-title":"Evaluation of the etiological and clinical characteristics of pediatric central diabetes insipidus","volume":"35","author":"Gasimova E","year":"2022","unstructured":"Gasimova E\n, \nBerberoglu M\n, \nOzsu E\n, et al.\n Evaluation of the etiological and clinical characteristics of pediatric central diabetes insipidus. J Pediatr Endocrinol Metab 2022 35 1089\u20131096. (https:\/\/doi.org\/10.1515\/jpem-2022-0058)"},{"key":"bib8","series-title":"Drug Saf","first-page":"449","article-title":"Drug-induced diabetes insipidus: incidence, prevention and management","volume":"21","author":"Bendz H","year":"1999","unstructured":"Bendz H\n & \nAurell M\n\n. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf 1999 21 449\u2013456. (https:\/\/doi.org\/10.2165\/00002018-199921060-00002)"},{"key":"bib9","series-title":"Front Oncol","article-title":"Immune checkpoint inhibitor-induced central diabetes insipidus: looking for the needle in the haystack or a very rare side-effect to promptly diagnose?","volume":"12","author":"Barnabei A","year":"2022","unstructured":"Barnabei A\n, \nStrigari L\n, \nCorsello A\n, et al.\n Immune checkpoint inhibitor-induced central diabetes insipidus: looking for the needle in the haystack or a very rare side-effect to promptly diagnose? Front Oncol 2022 12 798517. (https:\/\/doi.org\/10.3389\/fonc.2022.798517)"},{"key":"bib10","series-title":"Cureus","article-title":"Diabetes insipidus: a pragmatic approach to management","volume":"13","author":"Priya G","year":"2021","unstructured":"Priya G\n, \nKalra S\n, \nDasgupta A\n, et al.\n Diabetes insipidus: a pragmatic approach to management. Cureus 2021 13 e12498. (https:\/\/doi.org\/10.7759\/cureus.12498)"},{"key":"bib11","series-title":"Int J Med Sci","first-page":"796","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda T","year":"2013","unstructured":"Sakaeda T\n, \nTamon A\n, \nKadoyama K\n, et al.\n Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 2013 10 796\u2013803. (https:\/\/doi.org\/10.7150\/ijms.6048)"},{"key":"bib12","series-title":"Clin Exp Ophthalmol","first-page":"140","article-title":"Drug-associated glaucoma: a real-world study based on the Food and Drug Administration adverse event reporting system database","volume":"53","author":"Wu SN","year":"2024","unstructured":"Wu SN\n, \nChen XD\n, \nYan D\n, et al.\n Drug-associated glaucoma: a real-world study based on the Food and Drug Administration adverse event reporting system database. Clin Exp Ophthalmol 2024 53 140\u2013160. (https:\/\/doi.org\/10.1111\/ceo.14454)"},{"key":"bib13","series-title":"Front Pharmacol","article-title":"Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: a pharmacovigilance study of the FAERS database","volume":"14","author":"Zhao H","year":"2023","unstructured":"Zhao H\n, \nLi ZR\n, \nZhang Q\n, et al.\n Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: a pharmacovigilance study of the FAERS database. Front Pharmacol 2023 14 1110575. (https:\/\/doi.org\/10.3389\/fphar.2023.1110575)"},{"key":"bib14","series-title":"Acta Endocrinol","first-page":"270","article-title":"Lithium-induced nephrogenic diabetes insipidus responsive to desmopressin","volume":"15","author":"Senocak TE","year":"2019","unstructured":"Senocak TE\n, \nEralp H\n & \nKayatas K\n\n. Lithium-induced nephrogenic diabetes insipidus responsive to desmopressin. Acta Endocrinol 2019 15 270\u2013271. (https:\/\/doi.org\/10.4183\/aeb.2019.270)"},{"key":"bib15","series-title":"Cells","first-page":"1060","article-title":"Lithium chloride and GSK3 inhibition reduce aquaporin-2 expression in primary cultured inner medullary collecting duct cells due to independent mechanisms","volume":"9","author":"Kaiser M","year":"2020","unstructured":"Kaiser M\n & \nEdemir B\n\n. Lithium chloride and GSK3 inhibition reduce aquaporin-2 expression in primary cultured inner medullary collecting duct cells due to independent mechanisms. Cells 2020 9 1060. (https:\/\/doi.org\/10.3390\/cells9041060)"},{"key":"bib16","series-title":"Nat Rev Dis Primers","first-page":"54","article-title":"Diabetes insipidus","volume":"5","author":"Christ-Crain M","year":"2019","unstructured":"Christ-Crain M\n, \nBichet DG\n, \nFenske WK\n, et al.\n Diabetes insipidus. Nat Rev Dis Primers 2019 5 54. (https:\/\/doi.org\/10.1038\/s41572-019-0103-2)"},{"key":"bib17","series-title":"Prim Care Companion CNS Disord","article-title":"Diabetes insipidus secondary to combination atypical antipsychotic and lithium use in a bipolar disorder patient: a case report","volume":"13","author":"Rej S","year":"2011","unstructured":"Rej S\n, \nMargolese HC\n & \nLow NC\n\n. Diabetes insipidus secondary to combination atypical antipsychotic and lithium use in a bipolar disorder patient: a case report. Prim Care Companion CNS Disord 2011 13 PCC.11l01138. (https:\/\/doi.org\/10.4088\/pcc.11l01138)"},{"key":"bib18","series-title":"Indian J Psychol Med","first-page":"94","article-title":"Diabetes insipidus induced by oral olanzapine at therapeutic dose","volume":"45","author":"Kumar MP","year":"2023","unstructured":"Kumar MP\n, \nRamamurthy P\n, \nSolomon S\n, et al.\n Diabetes insipidus induced by oral olanzapine at therapeutic dose. Indian J Psychol Med 2023 45 94\u201395. (https:\/\/doi.org\/10.1177\/02537176221109962)"},{"key":"bib19","series-title":"Anaesth Intensive Care","first-page":"319","article-title":"Diabetes insipidus following overdose of baclofen and quetiapine","volume":"37","author":"Silversides JA","year":"2009","unstructured":"Silversides JA\n & \nScott KC\n\n. Diabetes insipidus following overdose of baclofen and quetiapine. Anaesth Intensive Care 2009 37 319\u2013320. (https:\/\/doi.org\/10.1177\/0310057x0903700218)"},{"key":"bib20","series-title":"Paediatr Anaesth","first-page":"250","article-title":"Dexmedetomidine-associated diabetes insipidus during skull base surgery in a pediatric patient","volume":"33","author":"Reynolds EG","year":"2023","unstructured":"Reynolds EG\n, \nVan Decar LM\n, \nSharpe EE\n, et al.\n Dexmedetomidine-associated diabetes insipidus during skull base surgery in a pediatric patient. Paediatr Anaesth 2023 33 250\u2013253. (https:\/\/doi.org\/10.1111\/pan.14587)"},{"key":"bib21","series-title":"Anaesthesiol Intensive Ther","first-page":"237","article-title":"Dexmedetomidine-induced diabetes insipidus during coronary artery bypass graft surgery","volume":"55","author":"Tang T","year":"2023","unstructured":"Tang T\n, \nWagle R\n, \nHasoon J\n, et al.\n Dexmedetomidine-induced diabetes insipidus during coronary artery bypass graft surgery. Anaesthesiol Intensive Ther 2023 55 237\u2013239. (https:\/\/doi.org\/10.5114\/ait.2023.130859)"},{"key":"bib22","series-title":"J Pharm Pract","first-page":"685","article-title":"Probable dexmedetomidine induced diabetes insipidus: a case review","volume":"36","author":"Vani S","year":"2023","unstructured":"Vani S\n, \nStackpole A\n & \nKovacevic MP\n\n. Probable dexmedetomidine induced diabetes insipidus: a case review. J Pharm Pract 2023 36 685\u2013688. (https:\/\/doi.org\/10.1177\/08971900211053261)"},{"key":"bib23","series-title":"Anesth Analg","first-page":"82","article-title":"Perioperative diabetes insipidus caused by anesthetic medications: a review of the literature","volume":"134","author":"Van Decar LM","year":"2022","unstructured":"Van Decar LM\n, \nReynolds EG\n, \nSharpe EE\n, et al.\n Perioperative diabetes insipidus caused by anesthetic medications: a review of the literature. Anesth Analg 2022 134 82\u201389. (https:\/\/doi.org\/10.1213\/ane.0000000000005344)"},{"key":"bib24","series-title":"Am J Kidney Dis","first-page":"628","article-title":"Pemetrexed-induced nephrogenic diabetes insipidus","volume":"68","author":"Fung E","year":"2016","unstructured":"Fung E\n, \nAnand S\n & \nBhalla V\n\n. Pemetrexed-induced nephrogenic diabetes insipidus. Am J Kidney Dis 2016 68 628\u2013632. (https:\/\/doi.org\/10.1053\/j.ajkd.2016.04.016)"},{"key":"bib25","series-title":"Medicine","article-title":"Severe hyponatremia and diabetes insipidus caused by low-dose cyclophosphamide in breast cancer patients: a case report and literature review","volume":"103","author":"Chen Y","year":"2024","unstructured":"Chen Y\n, \nLi L\n, \nOu R\n, et al.\n Severe hyponatremia and diabetes insipidus caused by low-dose cyclophosphamide in breast cancer patients: a case report and literature review. Medicine 2024 103 e37572. (https:\/\/doi.org\/10.1097\/md.0000000000037572)"},{"key":"bib26","series-title":"CEN Case Rep","first-page":"194","article-title":"A case of ifosfamide-induced acute kidney injury, Fanconi syndrome, and nephrogenic diabetes insipidus","volume":"13","author":"Hoang S","year":"2024","unstructured":"Hoang S\n, \nPujar T\n, \nBellorin-Font E\n, et al.\n A case of ifosfamide-induced acute kidney injury, Fanconi syndrome, and nephrogenic diabetes insipidus. CEN Case Rep 2024 13 194\u2013198. (https:\/\/doi.org\/10.1007\/s13730-023-00829-z)"},{"key":"bib27","series-title":"J Oncol Pharm Pract","first-page":"1040","article-title":"Central diabetes insipidus induced by temozolomide: a report of two cases","volume":"27","author":"Mahiat C","year":"2021","unstructured":"Mahiat C\n, \nCapes A\n, \nDuprez T\n, et al.\n Central diabetes insipidus induced by temozolomide: a report of two cases. J Oncol Pharm Pract 2021 27 1040\u20131045. (https:\/\/doi.org\/10.1177\/1078155220961551)"},{"key":"bib28","series-title":"Front Endocrinol","article-title":"Grading central diabetes insipidus induced by immune checkpoint inhibitors: a challenging task","volume":"13","author":"Barnabei A","year":"2022","unstructured":"Barnabei A\n, \nStrigari L\n, \nCorsello A\n, et al.\n Grading central diabetes insipidus induced by immune checkpoint inhibitors: a challenging task. Front Endocrinol 2022 13 840971. (https:\/\/doi.org\/10.3389\/fendo.2022.840971)"},{"key":"bib29","series-title":"Best Pract Res Clin Endocrinol Metab","article-title":"Endocrine immune-related adverse events: adrenal, parathyroid, diabetes insipidus, and lipoatrophy","volume":"36","author":"Atkinson M","year":"2022","unstructured":"Atkinson M\n & \nLansdown AJ\n\n. Endocrine immune-related adverse events: adrenal, parathyroid, diabetes insipidus, and lipoatrophy. Best Pract Res Clin Endocrinol Metab 2022 36 101635. (https:\/\/doi.org\/10.1016\/j.beem.2022.101635)"},{"key":"bib30","series-title":"Life Sci","article-title":"Letrozole: pharmacology, toxicity and potential therapeutic effects","volume":"310","author":"Mukherjee AG","year":"2022","unstructured":"Mukherjee AG\n, \nWanjari UR\n, \nNagarajan D\n, et al.\n Letrozole: pharmacology, toxicity and potential therapeutic effects. Life Sci 2022 310 121074. (https:\/\/doi.org\/10.1016\/j.lfs.2022.121074)"},{"key":"bib31","series-title":"Endocrinology","first-page":"2092","article-title":"Estradiol and testosterone regulate arginine-vasopressin expression in SH-SY5Y human female neuroblastoma cells through estrogen receptors-\u03b1 and -\u03b2","volume":"154","author":"Grassi D","year":"2013","unstructured":"Grassi D\n, \nBellini MJ\n, \nAcaz-Fonseca E\n, et al.\n Estradiol and testosterone regulate arginine-vasopressin expression in SH-SY5Y human female neuroblastoma cells through estrogen receptors-\u03b1 and -\u03b2. Endocrinology 2013 154 2092\u20132100. (https:\/\/doi.org\/10.1210\/en.2012-2137)"},{"key":"bib32","series-title":"J Obstet Gynaecol Res","first-page":"2009","article-title":"Estrogen-dependent oxytocin expression in the hypothalamus and estrogen-dependent vasopressin in the median eminence","volume":"50","author":"Nishimura K","year":"2024","unstructured":"Nishimura K\n, \nUeta Y\n & \nYoshino K\n\n. Estrogen-dependent oxytocin expression in the hypothalamus and estrogen-dependent vasopressin in the median eminence. J Obstet Gynaecol Res 2024 50 2009\u20132018. (https:\/\/doi.org\/10.1111\/jog.16100)"},{"key":"bib33","series-title":"J Card Fail","first-page":"615","article-title":"Doxycycline for chronic driveline infections can cause diabetes insipidus","volume":"29","author":"Kesari A","year":"2023","unstructured":"Kesari A\n, \nSchreck T\n, \nBenatti RD\n, et al.\n Doxycycline for chronic driveline infections can cause diabetes insipidus. J Card Fail 2023 29 615. (https:\/\/doi.org\/10.1016\/j.cardfail.2022.10.171)"},{"key":"bib34","series-title":"Cancer Treat Rev","article-title":"Targeting neuroendocrine tumors with octreotide and lanreotide: key points for clinical practice from NET specialists","volume":"117","author":"La Salvia A","year":"2023","unstructured":"La Salvia A\n, \nModica R\n, \nRossi RE\n, et al.\n Targeting neuroendocrine tumors with octreotide and lanreotide: key points for clinical practice from NET specialists. Cancer Treat Rev 2023 117 102560. (https:\/\/doi.org\/10.1016\/j.ctrv.2023.102560)"},{"key":"bib35","series-title":"J Drug Target","first-page":"569","article-title":"Octreotide and octreotide-derived delivery systems","volume":"31","author":"Fan M","year":"2023","unstructured":"Fan M\n, \nHuang Y\n, \nZhu X\n, et al.\n Octreotide and octreotide-derived delivery systems. J Drug Target 2023 31 569\u2013584. (https:\/\/doi.org\/10.1080\/1061186x.2023.2216895)"},{"key":"bib36","series-title":"J ASEAN Fed Endocr Soc","first-page":"220","article-title":"Diabetes insipidus induced by combination of short-acting octreotide and lanreotide for recurrent carcinoid crisis of neuroendocrine tumour: a case report","volume":"36","author":"Guan GK","year":"2021","unstructured":"Guan GK\n, \nRajoo S\n, \nDusa NM\n, et al.\n Diabetes insipidus induced by combination of short-acting octreotide and lanreotide for recurrent carcinoid crisis of neuroendocrine tumour: a case report. J ASEAN Fed Endocr Soc 2021 36 220\u2013222. (https:\/\/doi.org\/10.15605\/jafes.036.02.09)"},{"key":"bib37","series-title":"Am J Med Sci","first-page":"517","article-title":"Effect of dapagliflozin treatment on fluid and electrolyte balance in diabetic rats","volume":"352","author":"Chen L","year":"2016","unstructured":"Chen L\n, \nLaRocque LM\n, \nEfe O\n, et al.\n Effect of dapagliflozin treatment on fluid and electrolyte balance in diabetic rats. Am J Med Sci 2016 352 517\u2013523. (https:\/\/doi.org\/10.1016\/j.amjms.2016.08.015)"},{"key":"bib38","series-title":"Am J Physiol Endocrinol Metab","first-page":"E633","article-title":"Dehydration-induced AVP stimulates glucagon release and ketogenesis","volume":"328","author":"Hill TG","year":"2025","unstructured":"Hill TG\n, \nBriant LJB\n, \nKim A\n, et al.\n Dehydration-induced AVP stimulates glucagon release and ketogenesis. Am J Physiol Endocrinol Metab 2025 328 E633\u2013E644. (https:\/\/doi.org\/10.1152\/ajpendo.00505.2024)"},{"key":"bib39","series-title":"Diagnostics","first-page":"1194","article-title":"Sodium-glucose cotransporter 2 inhibitor combined with conventional diuretics ameliorate body fluid retention without excessive plasma volume reduction","volume":"14","author":"Asakura-Kinoshita M","year":"2024","unstructured":"Asakura-Kinoshita M\n, \nMasuda T\n, \nOka K\n, et al.\n Sodium-glucose cotransporter 2 inhibitor combined with conventional diuretics ameliorate body fluid retention without excessive plasma volume reduction. Diagnostics 2024 14 1194. (https:\/\/doi.org\/10.3390\/diagnostics14111194)"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/15\/1\/EC-25-0734.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/15\/1\/EC-25-0734.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/15\/1\/EC-25-0734.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:56:03Z","timestamp":1769766963000},"score":1,"resource":{"primary":{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/15\/1\/EC-25-0734.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":78,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/ec-25-0734","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]}}}